Rinvoq (upadacitinib) is a prescription medication primarily used to treat various forms of moderate to severe arthritis in adults. It's particularly effective when other treatments haven't worked well enough or haven't been tolerated.
Key Uses of Rinvoq:
-
Rheumatoid Arthritis (RA): Rinvoq is indicated for treating moderate to severe active rheumatoid arthritis in adults who haven't responded adequately to, or can't tolerate, one or more TNF blockers (a type of arthritis medication). This is a major application, supported by numerous sources including the official Rinvoq website https://www.rinvoq.com and the European Medicines Agency (EMA) https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq.
-
Psoriatic Arthritis: Rinvoq also effectively treats moderate to severely active psoriatic arthritis in adults. This information is confirmed by multiple sources, such as Rinvoq's New Zealand website https://rinvoq.co.nz/rinvoq/what-is-rinvoq.
-
Ankylosing Spondylitis (AS): Rinvoq is used to treat active ankylosing spondylitis, a form of arthritis primarily affecting the spine, in adults.
-
Non-radiographic Axial Spondyloarthritis: Rinvoq is also indicated for the treatment of active non-radiographic axial spondyloarthritis in adults, which similarly involves inflammation in the spine, resulting in back pain reduction.
It's crucial to remember that Rinvoq is a prescription medication, and its use should be under the guidance of a healthcare professional. The information provided here is for general knowledge and should not be considered medical advice. Always consult a doctor before starting any new medication.
